APA (7th ed.) Citation

J, B., IS, M., JF, O., L, T., AC, O., Q, C., . . . K, B. (2026). Bevacizumab for Metastatic Colorectal Cancer with Chromosomal Instability: Cost-Effectiveness Analysis for a Novel Precision Treatment Approach in Germany, Ireland and Spain. PharmacoEconomics, 44(3), 359. https://doi.org/10.1007/s40273-025-01585-x

Chicago Style (17th ed.) Citation

J, Briody, et al. "Bevacizumab for Metastatic Colorectal Cancer with Chromosomal Instability: Cost-Effectiveness Analysis for a Novel Precision Treatment Approach in Germany, Ireland and Spain." PharmacoEconomics 44, no. 3 (2026): 359. https://doi.org/10.1007/s40273-025-01585-x.

MLA (9th ed.) Citation

J, Briody, et al. "Bevacizumab for Metastatic Colorectal Cancer with Chromosomal Instability: Cost-Effectiveness Analysis for a Novel Precision Treatment Approach in Germany, Ireland and Spain." PharmacoEconomics, vol. 44, no. 3, 2026, p. 359, https://doi.org/10.1007/s40273-025-01585-x.